Lexicon Pharmaceuticals, Inc. (LXRX) Stock Price & Analysis

Lexicon Pharmaceuticals, Inc. (LXRX) rose 0.00% to USD 1.88 as of June 10, 2026 at 06:53 UTC, according to Nexqual real-time market data.

LXRX last closed at USD 1.88; the session ranged USD 1.84–1.93 on volume of 1,262,124 shares. Market capitalization is $835.09M, with a 52-week range of USD 0.64–2.53 (NCM). Source: Nexqual, June 10, 2026 at 06:53 UTC.

Key Statistics (as of June 10, 2026 at 06:53 UTC)

Technical Analysis (LXRX)

Nexqual's technical model rates LXRX "NEUTRAL" based on 3 bullish and 3 bearish signals across 123 daily candles, as of June 10, 2026 at 06:53 UTC.

Analyst Ratings (LXRX)

Wall Street analysts rate LXRX "Buy" based on 5 analysts, with a mean price target of USD 3.72 (range USD 1.5–6), per Nexqual as of June 10, 2026 at 06:53 UTC.

Earnings (LXRX)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 06:53 UTC.

Financials & Fundamentals (LXRX)

Source: Nexqual, June 10, 2026 at 06:53 UTC.

Financial Health Score (LXRX)

Nexqual rates Lexicon Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 06:53 UTC.

Ownership (LXRX)

Source: Nexqual, June 10, 2026 at 06:53 UTC.

Leadership (LXRX)

Lexicon Pharmaceuticals, Inc. is led by Michael S. Exton (age 55), CEO & Director, per Nexqual as of June 10, 2026 at 06:53 UTC.

Major Backers & Investors (LXRX)

Notable institutional backers of Lexicon Pharmaceuticals, Inc. include Artal Group S.A., FMR, LLC, Siren, L.L.C., according to Nexqual as of June 10, 2026 at 06:53 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 06:53 UTC.

From Lexicon Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)

Key Strengths & Strategy (as disclosed to the SEC)

• Food and Drug Administration, or FDA, issued complete response letters regarding our New Drug Application, or NDA, for ZYNQUISTA in type 1 diabetes in March 2019 and December 2024.
• We use "sotagliflozin" when referring to our development for HCM, "ZYNQUISTA" when referring to our development for type 1 diabetes and "INPEFA" when referring to our FDA-approved drug.
• The FDA has various programs, including Fast Track, priority review and accelerated approval, which are intended to expedite or simplify the process for developing and reviewing promising drugs, or to provide for the approval of a drug on the basis of a surrogate endpoint.
• We have received Fast Track designation from the FDA for development of pilavapadin in that indication and are currently advancing third party collaboration discussions for its further development and commercialization. • We have developed LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders.

Partnerships

• We also seek to collaborate with other pharmaceutical and biotechnology companies, research institutes and academic institutions to capitalize on our drug target discoveries.   4 Novo Nordisk We entered into an exclusive license agreement with Novo Nordisk A/S in March 2025 under which we granted Novo Nordisk an exclusive, worldwide, royalty-bearing right and license to develop, manufacture and commercialize LX9851.
• Viatris We entered into an exclusive license agreement with Viatris Inc. in October 2024 under which we granted Viatris an exclusive, royalty-bearing right and license to develop and commercialize sotagliflozin in the licensed territory.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 06:53 UTC. This page is informational and not investment advice.